{"id":3725,"date":"2014-08-28T12:02:57","date_gmt":"2014-08-28T02:02:57","guid":{"rendered":"http:\/\/www.spinalcure.org.au\/?p=3725"},"modified":"2014-08-28T12:02:57","modified_gmt":"2014-08-28T02:02:57","slug":"stem-cell-phase-12a-clinical-trial-cervical-complete-spinal-cord-injury","status":"publish","type":"post","link":"https:\/\/www.spinalcure.org.au\/research\/stem-cell-phase-12a-clinical-trial-cervical-complete-spinal-cord-injury\/","title":{"rendered":"Stem cell phase 1\/2a clinical trial for cervical complete spinal cord injury"},"content":{"rendered":"

Following successful results from its Phase 1 trial, California company Asterias Biotherapeutics Inc. will now initiate a Phase 1\/2a clinical trial of its stem cell product, AST-OPC1, in patients with complete cervical spinal cord injury.<\/p>\n

The new clinical trial differs from the original clinical study in that doses up to 10 times higher will be tested. It will be an open-label, single-arm study testing three escalating doses of AST-OPC1 in 13 patients with C5-C7, neurologically-complete cervical spinal cord injury. The cells\u00a0will be administered 14 to 30 days post-injury. Selection of the clinical trial sites is well underway and the Company expects to begin patient enrollment during the first quarter of 2015.<\/p>\n

Read more\u2026<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\n
\nFollowing successful results from its Phase 1 trial, California company Asterias Biotherapeutics Inc. will now initiate a Phase 1\/2a clinical trial of its stem cell product, AST-OPC1, in patients with complete cervical spinal cord injury. The new clinical trial differs…\n<\/div>\n